FindTrial
Sign In

Cabiralizumab

BIOLOGICAL9 trials

Sponsors

Five Prime Therapeutics, Inc., Bristol-Myers Squibb, University of Chicago, Yale University, Hitendra Patel

Conditions

Advanced CancerAdvanced MalignanciesAdvanced MelanomaAdvanced Pancreatic CancerAdvanced Solid TumorsCancerHead and Neck CancerMalignant Glioma

Phase 1

Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
CompletedNCT02526017
Five Prime Therapeutics, Inc.Advanced Solid Tumors, Head and Neck Cancer, Malignant Glioma +4
Start: 2015-09-08End: 2019-11-18Updated: 2022-03-09
A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread
CompletedNCT03158272
Bristol-Myers SquibbAdvanced Malignancies
Start: 2017-05-25End: 2019-10-23Updated: 2020-12-21
An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment
CompletedNCT03335540
Bristol-Myers SquibbAdvanced Cancer
Start: 2018-05-07End: 2021-08-25Updated: 2022-09-26
Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer
CompletedNCT03431948
University of ChicagoCancer
Start: 2018-03-15End: 2022-04-11Updated: 2023-02-16
APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
CompletedNCT03502330
Yale UniversityAdvanced Melanoma, Non-small Cell Lung Cancer, Renal Cell Carcinoma
Start: 2018-06-09End: 2024-05-15Updated: 2024-07-03
Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Active, not recruitingNCT04331067
Washington University School of MedicineTriple Negative Breast Cancer
Start: 2020-11-19End: 2026-05-31Updated: 2025-04-23

Phase 2

A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
CompletedNCT03336216
Bristol-Myers SquibbAdvanced Pancreatic Cancer
Start: 2017-12-18End: 2023-06-01Updated: 2024-07-23
Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer
CompletedNCT03697564
Hitendra PatelPancreatic Cancer Stage IV
Start: 2019-10-31End: 2023-07-13Updated: 2025-08-06
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
CompletedNCT03927105
University of Michigan Rogel Cancer CenterPeripheral T Cell Lymphoma
Start: 2019-04-25End: 2023-07-06Updated: 2024-03-18

Related Papers

Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial
Journal for ImmunoTherapy of Cancer2025-05-013 citations
Phase Ib/II Study of Lacnotuzumab in Combination with Spartalizumab in Patients with Advanced Malignancies
Journal of Immunotherapy and Precision Oncology2023-11-249 citations
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better.
2023-11-149 citations
Abstract P3-06-07: Phase Ib/II study to evaluate safety and tolerability of cabiralizumab in combination with nivolumab and neoadjuvant chemotherapy in patients with localized triple-negative breast cancer
Cancer Research2023-03-012 citations
ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study
Clinical Cancer Research2022-03-1847 citations
GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors.
2021-08-0136 citations
A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Clinical Cancer Research2021-06-1790 citations
A randomized phase II study of cabiralizumab (cabira) + nivolumab (nivo) ± chemotherapy (chemo) in advanced pancreatic ductal adenocarcinoma (PDAC).
Journal of Clinical Oncology2019-01-2949 citations
Characterization of the immune tumor microenvironment (TME) to inform personalized medicine with immuno-oncology (IO) combinations
Annals of Oncology2018-10-012 citations
Pharmacodynamics (PD) and genomic profiling of pts treated with cabiralizumab (cabira) + nivolumab (NIVO) provide evidence of on-target tumor immune modulations and support future clinical applications.
Journal of Clinical Oncology2018-05-2014 citations
Phase 1, open-label, adaptive biomarker trial that informs the evolution of combination immuno-oncology (IO) therapies (ADVISE), a precision IO approach to personalized medicine.
Journal of Clinical Oncology2018-05-203 citations
Trial in progress: Platform phase 1 study investigating the safety of stereotactic body radiotherapy with immuno-oncology agents for the treatment of multiple metastases in advanced solid tumors.
Journal of Clinical Oncology2018-05-20